We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Shares of ImmuCell Corporation (ICCC - Free Report) have fallen sharply since the release of third-quarter 2025 earnings. The stock has declined 22.7% since the announcement compared with a 3.9% drop of the S&P 500 over the same period. Over the past month, ImmuCell shares are down 23.1%, while the broader index has slipped a more modest 2%. This underperformance reflects heightened investor caution despite notable operational improvements reported by the company.
Sales & Revenue Performance
ImmuCell’s third-quarter results show mixed top-line performance but significant gains in profitability. Product sales for the third quarter decreased 8% year over year to $5.5 million from $6 million, primarily due to timing-related shipment fluctuations and the lingering effects of earlier supply constraints.
However, profitability metrics strengthened. Gross margin jumped to 43% from 26% a year earlier, reflecting better production yields and a cumulative price increase of roughly 6% referenced during the earnings call. The company’s quarterly net loss narrowed to $140,000, or 2 cents per share from a loss of $702,000, or 9 cents per share, in the prior-year quarter.
On a year-to-date basis, the turnaround was more pronounced. ImmuCell posted net income of $1.8 million for the first nine months of 2025 versus a net loss of $2.7 million a year earlier, driven by higher sales, improved margins and a 7.4% reduction in operating expenses.
ImmuCell Corporation Price, Consensus and EPS Surprise
Operating income improved to a modest $20,000 in the third quarter, a reversal from a $575,000 operating loss in the prior-year period. Adjusted EBITDA grew substantially, reaching approximately $751,000 for the quarter versus $196,000 a year earlier, underscoring improved operational efficiency.
For the first nine months of 2025, adjusted EBITDA rose to $4.4 million from just $35,000 in the same period of 2024. Cash and cash equivalents at quarter-end were $3.9 million, up slightly from $3.8 million at the end of 2024, despite investment in inventory to support peak selling season demand. Working capital also expanded meaningfully to $12.8 million, reflecting stronger balance sheet positioning.
Domestic sales showed resilience, rising 2% year over year in the quarter and 9.5% from the second quarter, according to management. International sales, particularly to Canada, declined due to shipment timing and allocation decisions during periods of constrained supply. However, for the first nine months of 2025, international revenue increased 15% year over year.
Management Commentary
Management emphasized that the company has exited the prolonged order backlog that had constrained growth in recent years. Executives noted that the distribution pipeline has now normalized, enabling the sales team to resume customer acquisition efforts rather than managing shortages. The new CEO, Olivier te Boekhorst, highlighted the company’s focus on operational excellence, customer engagement and consistent product availability.
The CFO added that improved manufacturing performance—along with pricing actions—was the primary driver of margin expansion. Leadership also underscored the importance of disciplined inventory management, especially regarding frozen colostrum, a critical input for First Defense production.
Factors Influencing the Headline Numbers
The year-over-year decline in quarterly sales was shaped largely by the unwinding of backlog dynamics. As the company rebuilt inventory earlier in the year, distributors were heavily restocked, temporarily pulling sales forward. This led to softer quarterly comparisons in the second half of 2025—an outcome management had previously signaled.
Gross margin improvement reflected several factors: enhanced production yields, the benefits of scale from higher year-to-date sales and a composite price increase implemented in 2025. Management also noted reduced product development spending, particularly on Re-Tain, as a contributing factor in the improved cost structure.
Forward-Looking Considerations
The company provided qualitative expectations. It anticipates that difficult year-over-year comparisons may continue into the next several quarters due to the prior backlog fulfillment, with normalization expected by the second half of 2026. The team is prioritizing operational discipline, expanded customer engagement and reinvestment in First Defense commercial opportunities.
Regarding Re-Tain, its novel mastitis treatment, management reiterated that FDA approval remains pending. Meanwhile, investigational product use, conducted in partnership with Michigan State University, is underway to gather field performance feedback that will help shape launch strategy once approval is secured.
Other Developments
Beyond financial results, the company is undergoing a leadership transition. Long-serving executive Michael Brigham is stepping back as Olivier te Boekhorst assumes the role of president and CEO. Additionally, ImmuCell continues to evaluate its previously announced investments in production capacity and aseptic filling capabilities. Some capital projects remain paused due to cash constraints, with approximately $2 million in remaining Re-Tain-related investment deferred for the time being.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ICCC Stock Down Despite Y/Y Q3 Earnings Improvement & Margin Strength
Shares of ImmuCell Corporation (ICCC - Free Report) have fallen sharply since the release of third-quarter 2025 earnings. The stock has declined 22.7% since the announcement compared with a 3.9% drop of the S&P 500 over the same period. Over the past month, ImmuCell shares are down 23.1%, while the broader index has slipped a more modest 2%. This underperformance reflects heightened investor caution despite notable operational improvements reported by the company.
Sales & Revenue Performance
ImmuCell’s third-quarter results show mixed top-line performance but significant gains in profitability. Product sales for the third quarter decreased 8% year over year to $5.5 million from $6 million, primarily due to timing-related shipment fluctuations and the lingering effects of earlier supply constraints.
However, profitability metrics strengthened. Gross margin jumped to 43% from 26% a year earlier, reflecting better production yields and a cumulative price increase of roughly 6% referenced during the earnings call. The company’s quarterly net loss narrowed to $140,000, or 2 cents per share from a loss of $702,000, or 9 cents per share, in the prior-year quarter.
On a year-to-date basis, the turnaround was more pronounced. ImmuCell posted net income of $1.8 million for the first nine months of 2025 versus a net loss of $2.7 million a year earlier, driven by higher sales, improved margins and a 7.4% reduction in operating expenses.
ImmuCell Corporation Price, Consensus and EPS Surprise
ImmuCell Corporation price-consensus-eps-surprise-chart | ImmuCell Corporation Quote
Other Key Business Metrics
Operating income improved to a modest $20,000 in the third quarter, a reversal from a $575,000 operating loss in the prior-year period. Adjusted EBITDA grew substantially, reaching approximately $751,000 for the quarter versus $196,000 a year earlier, underscoring improved operational efficiency.
For the first nine months of 2025, adjusted EBITDA rose to $4.4 million from just $35,000 in the same period of 2024. Cash and cash equivalents at quarter-end were $3.9 million, up slightly from $3.8 million at the end of 2024, despite investment in inventory to support peak selling season demand. Working capital also expanded meaningfully to $12.8 million, reflecting stronger balance sheet positioning.
Domestic sales showed resilience, rising 2% year over year in the quarter and 9.5% from the second quarter, according to management. International sales, particularly to Canada, declined due to shipment timing and allocation decisions during periods of constrained supply. However, for the first nine months of 2025, international revenue increased 15% year over year.
Management Commentary
Management emphasized that the company has exited the prolonged order backlog that had constrained growth in recent years. Executives noted that the distribution pipeline has now normalized, enabling the sales team to resume customer acquisition efforts rather than managing shortages. The new CEO, Olivier te Boekhorst, highlighted the company’s focus on operational excellence, customer engagement and consistent product availability.
The CFO added that improved manufacturing performance—along with pricing actions—was the primary driver of margin expansion. Leadership also underscored the importance of disciplined inventory management, especially regarding frozen colostrum, a critical input for First Defense production.
Factors Influencing the Headline Numbers
The year-over-year decline in quarterly sales was shaped largely by the unwinding of backlog dynamics. As the company rebuilt inventory earlier in the year, distributors were heavily restocked, temporarily pulling sales forward. This led to softer quarterly comparisons in the second half of 2025—an outcome management had previously signaled.
Gross margin improvement reflected several factors: enhanced production yields, the benefits of scale from higher year-to-date sales and a composite price increase implemented in 2025. Management also noted reduced product development spending, particularly on Re-Tain, as a contributing factor in the improved cost structure.
Forward-Looking Considerations
The company provided qualitative expectations. It anticipates that difficult year-over-year comparisons may continue into the next several quarters due to the prior backlog fulfillment, with normalization expected by the second half of 2026. The team is prioritizing operational discipline, expanded customer engagement and reinvestment in First Defense commercial opportunities.
Regarding Re-Tain, its novel mastitis treatment, management reiterated that FDA approval remains pending. Meanwhile, investigational product use, conducted in partnership with Michigan State University, is underway to gather field performance feedback that will help shape launch strategy once approval is secured.
Other Developments
Beyond financial results, the company is undergoing a leadership transition. Long-serving executive Michael Brigham is stepping back as Olivier te Boekhorst assumes the role of president and CEO. Additionally, ImmuCell continues to evaluate its previously announced investments in production capacity and aseptic filling capabilities. Some capital projects remain paused due to cash constraints, with approximately $2 million in remaining Re-Tain-related investment deferred for the time being.